Anticancer agent 308 

Anticancer agent 308 (compound 3s) is an AKT inhibitor with antitumor activity. Anticancer agent 308 reduces total AKT protein levels, thereby inhibiting the pro-survival PI3K/AKT signaling pathway. Anticancer agent 308 induces apoptosis, disrupts mitochondrial membrane potential, promotes reactive oxygen species (ROS) accumulation in mitochondria, and induces cell cycle arrest. Anticancer agent 308 inhibits cancer cell migration. Anticancer agent 308 is applicable to research related to breast cancer, lung adenocarcinoma, cervical cancer, prostate cancer, and hepatocellular carcinoma^[1].

Anticancer agent 308 (compound 3s) (IC₅₀ 1.16-4.23 μM) potently inhibits viability of MCF-7, MDA-MB-231, MDA-MB-468, A549, HepG2, HeLa, and PC-3 cancer cells at low micromolar concentrations while sparing normal NKE cells (IC₅₀ 84.15 μM), resulting in high selectivity indices^[1].
Anticancer agent 308 (compound 3s) induces dose-dependent cell death and reduces colony formation in MDA-MB-231 cells, while having minimal toxicity to NKE cells^[1].
Anticancer agent 308 (compound 3s) (0.5-2 μM; 24 h) induces concentration-dependent caspase-3-mediated apoptosis in MDA-MB-231 cells, with 66.8% apoptosis observed at 2 μM for 24 h^[1].
Anticancer agent 308 (compound 3s) (0.5-2 μM; 24 h) induces concentration-dependent activation of caspase-3/7 in MDA-MB-231 cells, reaching 4.16-fold activity at 2 μM for 24 h^[1].
Anticancer agent 308 (compound 3s) (0.5-2 μM; 24 h) induces concentration-dependent G2/M phase cell cycle arrest and increases subG0 apoptotic cell accumulation in MDA-MB-231 cells, with 50.43% of cells in G2/M phase at 2 μM for 24 h^[1].
Anticancer agent 308 (compound 3s) modulates expression and activation of apoptosis-related proteins (Bax, caspase-3, PARP) and suppresses AKT in MDA-MB-231 cells^[1].
Anticancer agent 308 (compound 3s) (0.5-2 μM; 24 h) induces concentration-dependent accumulation of intracellular and mitochondrial ROS in MDA-MB-231 cells, with 3.78-fold intracellular ROS and 2.89-fold mitochondrial ROS at 2 μM for 24 h, and this effect is suppressed by NAC pre-treatment^[1].
Anticancer agent 308 (compound 3s) (0.5-2 μM; 24 h) induces concentration-dependent cleavage of PARP in MDA-MB-231 cells, reaching 4.25-fold fluorescence intensity at 2 μM for 24 h^[1].
Anticancer agent 308 (compound 3s) (0.5-2 μM; 24 h) induces concentration-dependent mitochondrial depolarization in MDA-MB-231 cells, with only 20.81% of cells retaining polarized mitochondria at 2 μM for 24 h^[1].
Anticancer agent 308 (compound 3s) (0.5-2 μM; 24 h) inhibits MDA-MB-231 cell migration in a concentration-dependent manner, reducing wound closure to 41.2% and Transwell migration to 27.8% at 2 μM for 24 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

265.27

C₁₅H₁₁N₃O₂

NC(C1=C(C2=CC=CC=C2)N=C3C=CC=CN3C1=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kumar G, et al. Natural product inspired scaffold hopping strategy: Identification of potent anticancer 2-arylpyridopyrimidinones that induce cytoplasmic and mitochondrial ROS and G₂/M arrest. Bioorg Chem. 2026;172:109595.  [Content Brief]